TipRanks
Recursion Pharmaceuticals (MX:RXRX)
:RXRX
Mexico Market
RXRX
Recursion Pharmaceuticals
RESEARCH TOOLSreports

Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Target

7 Followers
See the Price Targets and Ratings of:

RXRX Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
2 Buy
3 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Recursion
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RXRX Stock 12 Month Forecast

Average Price Target

$124.06
▲(108.89% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in the last 3 months. The average price target is $124.06 with a high forecast of $149.62 and a low forecast of $110.34. The average price target represents a 108.89% change from the last price of $59.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","101":"$101","150":"$150","76.5":"$76.5","125.5":"$125.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":149.61660744,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$149.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124.057103669,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$124.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.34224798700001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,76.5,101,125.5,150],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.64,81.33050826461539,87.02101652923076,92.71152479384615,98.40203305846154,104.09254132307692,109.7830495876923,115.47355785230769,121.16406611692307,126.85457438153846,132.54508264615384,138.23559091076922,143.9260991753846,{"y":149.61660744,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.64,79.36439258992307,83.08878517984616,86.81317776976923,90.53757035969231,94.26196294961538,97.98635553953847,101.71074812946154,105.43514071938462,109.15953330930769,112.88392589923077,116.60831848915385,120.33271107907692,{"y":124.057103669,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.64,78.3094036913077,80.97880738261539,83.64821107392308,86.31761476523077,88.98701845653846,91.65642214784616,94.32582583915385,96.99522953046154,99.66463322176924,102.33403691307693,105.00344060438462,107.67284429569231,{"y":110.34224798700001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.89,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.61,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.19,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.64,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$149.62Average Price Target$124.06Lowest Price Target$110.34
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on MX:RXRX
Gil Blum
Needham
Needham
$149.62
Buy
151.92%
Upside
Reiterated
10/19/26
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (NASDAQ: RXRX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Morgan Stanley Analyst forecast on MX:RXRX
Sean Laaman
Morgan Stanley
Morgan Stanley
$99.12→$110.34
Hold
85.79%
Upside
Assigned
10/16/26
Morgan Stanley Remains a Hold on Recursion Pharmaceuticals (RXRX)
Bank of America Securities Analyst forecast on MX:RXRX
Alec Stranahan
Bank of America Securities
Bank of America Securities
$130.91→$112.21
Hold
88.94%
Upside
Reiterated
10/16/26
Bank of America Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
J.P. Morgan Analyst forecast on MX:RXRX
Priyanka Grover
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (NASDAQ: RXRX), Teladoc (NYSE: TDOC) and Oscar Health (NYSE: OSCR)
TD Cowen Analyst forecast on MX:RXRX
Brendan Smith
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/05/26
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on MX:RXRX
Gil Blum
Needham
Needham
$149.62
Buy
151.92%
Upside
Reiterated
10/19/26
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (NASDAQ: RXRX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Morgan Stanley Analyst forecast on MX:RXRX
Sean Laaman
Morgan Stanley
Morgan Stanley
$99.12→$110.34
Hold
85.79%
Upside
Assigned
10/16/26
Morgan Stanley Remains a Hold on Recursion Pharmaceuticals (RXRX)
Bank of America Securities Analyst forecast on MX:RXRX
Alec Stranahan
Bank of America Securities
Bank of America Securities
$130.91→$112.21
Hold
88.94%
Upside
Reiterated
10/16/26
Bank of America Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
J.P. Morgan Analyst forecast on MX:RXRX
Priyanka Grover
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (NASDAQ: RXRX), Teladoc (NYSE: TDOC) and Oscar Health (NYSE: OSCR)
TD Cowen Analyst forecast on MX:RXRX
Brendan Smith
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/05/26
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OMCLOmnicell
PVLAPalvella Therapeutics
ZVRAZevra Therapeutics
STOKStoke Therapeutics
AMRXAmneal Pharmaceuticals
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Recursion Pharmaceuticals

3 Months
Gil BlumNeedham
Success Rate
13/28 ratings generated profit
46%
Average Return
+3.63%
Copying Gil Blum's trades and holding each position for 3 Months would result in 46.43% of your transactions generating a profit, with an average return of +3.63% per trade.
1 Year
Gil BlumNeedham
Success Rate
8/28 ratings generated profit
29%
Average Return
-15.51%
Copying Gil Blum's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -15.51% per trade.
2 Years
Gil BlumNeedham
Success Rate
4/28 ratings generated profit
14%
Average Return
-30.03%
Copying Gil Blum's trades and holding each position for 2 Years would result in 14.29% of your transactions generating a profit, with an average return of -30.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RXRX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
3
1
1
1
2
Buy
0
0
0
1
1
Hold
4
4
4
5
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
5
5
7
10
In the current month, RXRX has received 3 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. RXRX average Analyst price target in the past 3 months is 124.06.
Each month's total comprises the sum of three months' worth of ratings.

RXRX Financial Forecast

RXRX Earnings Forecast

Next quarter’s earnings estimate for RXRX is -$4.10 with a range of -$4.68 to -$2.99. The previous quarter’s EPS was -$4.68. RXRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RXRX has Performed in-line its overall industry.
Next quarter’s earnings estimate for RXRX is -$4.10 with a range of -$4.68 to -$2.99. The previous quarter’s EPS was -$4.68. RXRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RXRX has Performed in-line its overall industry.

RXRX Sales Forecast

Next quarter’s sales forecast for RXRX is $276.90M with a range of $154.85M to $568.54M. The previous quarter’s sales results were $143.44M. RXRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RXRX has Performed in-line its overall industry.
Next quarter’s sales forecast for RXRX is $276.90M with a range of $154.85M to $568.54M. The previous quarter’s sales results were $143.44M. RXRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RXRX has Performed in-line its overall industry.

RXRX Stock Forecast FAQ

What is MX:RXRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Recursion Pharmaceuticals’s 12-month average price target is 124.06.
    What is MX:RXRX’s upside potential, based on the analysts’ average price target?
    Recursion Pharmaceuticals has 108.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Recursion Pharmaceuticals a Buy, Sell or Hold?
          Recursion Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Recursion Pharmaceuticals’s share price target?
            The average share price target for Recursion Pharmaceuticals is 124.06. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $149.62 ,and the lowest forecast is $110.34. The average share price target represents 108.89% Increase from the current price of $59.39.
              What do analysts say about Recursion Pharmaceuticals?
              Recursion Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Recursion Pharmaceuticals?
                To buy shares of MX:RXRX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.